Strand Therapeutics is pioneering a groundbreaking approach in cancer treatment by utilizing programmed mRNA to specifically target cancer cells, minimizing toxicity in non-target tissues. Their method involves programming mRNA to produce the inflammatory protein IL-12 directly within tumors, thereby activating the immune system to attack cancer. This innovative approach, which is now entering clinical trials for patients with solid tumors, offers hope for more effective and safer cancer therapies.

Basic information

Country

USA

Group Name

Strand Therapeutics

Source

Source